Integral Diagnostics Ltd (ASX: IDX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Integral Diagnostics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Integral Diagnostics Ltd (ASX: IDX)
Latest News
Healthcare Shares
Integral Diagnostics posts profit and dividend growth in FY26
Cheap Shares
2 ASX shares tipped to grow 40% or more in the next 12 months
Healthcare Shares
2 ASX healthcare stocks tipped to return 34% to 63%
Healthcare Shares
Integral Diagnostics: FY26 results and new CFO appointment
Cheap Shares
2 ASX shares highly recommended to buy: Experts
Healthcare Shares
Analysts agree, this healthcare company's shares are looking cheap
Small Cap Shares
3 super small-cap ASX shares that could be destined for big things
Healthcare Shares
What are the healthcare stocks where RBC Capital Markets thinks you can make money?
Healthcare Shares
Bell Potter names the best ASX healthcare shares to buy in 2026
Small Cap Shares
3 of the best Australian small cap shares to buy for 2026
Healthcare Shares
Macquarie predicts this ASX All Ords healthcare stock to surge past $1 billion over the next 12 months
Small Cap Shares
2 ASX small-cap shares to buy right now
Frequently Asked Questions
-
Yes, Integral Diagnostics historically pays two fully franked dividends a year.
-
Integral Diagnostics generally pays its shareholder dividends in April and October.
-
Integral Diagnostics Ltd listed on the ASX on 21 October 2015.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 28 Aug 2026 | $0.0600 | 100.00% | Final | 02 Oct 2026 |
| 04 Mar 2026 | $0.0330 | 100.00% | Interim | 02 Apr 2026 |
| 29 Aug 2025 | $0.0400 | 100.00% | Final | 03 Oct 2025 |
| 06 Mar 2025 | $0.0250 | 100.00% | Interim | 07 Apr 2025 |
| 30 Aug 2024 | $0.0330 | 100.00% | Final | 03 Oct 2024 |
| 29 Feb 2024 | $0.0250 | 100.00% | Interim | 02 Apr 2024 |
| 31 Aug 2023 | $0.0350 | 100.00% | Final | 04 Oct 2023 |
| 02 Mar 2023 | $0.0250 | 100.00% | Interim | 04 Apr 2023 |
| 01 Sep 2022 | $0.0300 | 100.00% | Final | 05 Oct 2022 |
| 01 Mar 2022 | $0.0400 | 100.00% | Interim | 04 Apr 2022 |
| 02 Sep 2021 | $0.0700 | 100.00% | Final | 06 Oct 2021 |
| 01 Mar 2021 | $0.0550 | 100.00% | Interim | 06 Apr 2021 |
| 28 Aug 2020 | $0.0400 | 100.00% | Final | 01 Oct 2020 |
| 28 Feb 2020 | $0.0550 | 100.00% | Interim | 07 Apr 2020 |
| 30 Aug 2019 | $0.0500 | 100.00% | Final | 02 Oct 2019 |
| 01 Mar 2019 | $0.0500 | 100.00% | Interim | 02 Apr 2019 |
| 31 Aug 2018 | $0.0400 | 100.00% | Final | 04 Oct 2018 |
| 31 Jan 2018 | $0.0400 | 100.00% | Interim | 05 Mar 2018 |
| 31 Aug 2017 | $0.0000 | 100.00% | Final | 04 Oct 2017 |
| 28 Feb 2017 | $0.0300 | 100.00% | Interim | 30 Mar 2017 |
| 31 Aug 2016 | $0.0400 | 100.00% | Final | 04 Oct 2016 |
IDX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Integral Diagnostics Ltd
Integral Diagnostics Ltd (ASX: IDX) is an Australian healthcare services company providing medical imaging services. The group operates in a single business providing diagnostic imaging to general practitioners, medical specialists, and allied health professionals and their patients.
Following its transformational merger with Capitol Health, completed in December 2024, the combined group operates more than 155 radiology clinics across Australia and New Zealand, supported by over 350 radiologists. IDX is also a joint venture partner in Medx, expanding its services to the United Kingdom and Ireland.
IDX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 10 Sep 2026 | $2.29 | $-0.02 | -0.87% | 761,559 | $2.30 | $2.31 | $2.27 |
| 09 Sep 2026 | $2.31 | $-0.04 | -1.70% | 528,597 | $2.28 | $2.33 | $2.28 |
| 08 Sep 2026 | $2.35 | $0.02 | 0.86% | 515,418 | $2.34 | $2.35 | $2.32 |
| 07 Sep 2026 | $2.33 | $0.02 | 0.87% | 591,314 | $2.32 | $2.35 | $2.30 |
| 04 Sep 2026 | $2.31 | $0.03 | 1.32% | 1,498,450 | $2.28 | $2.31 | $2.27 |
| 03 Sep 2026 | $2.28 | $-0.07 | -2.98% | 1,282,998 | $2.35 | $2.35 | $2.27 |
| 02 Sep 2026 | $2.35 | $0.01 | 0.43% | 1,452,161 | $2.34 | $2.40 | $2.32 |
| 01 Sep 2026 | $2.34 | $0.05 | 2.18% | 1,561,857 | $2.30 | $2.35 | $2.26 |
| 31 Aug 2026 | $2.29 | $0.04 | 1.78% | 728,758 | $2.25 | $2.31 | $2.25 |
| 28 Aug 2026 | $2.25 | $-0.08 | -3.43% | 885,013 | $2.27 | $2.31 | $2.25 |
| 27 Aug 2026 | $2.33 | $0.00 | 0.00% | 2,039,066 | $2.33 | $2.33 | $2.30 |
| 26 Aug 2026 | $2.33 | $-0.07 | -2.92% | 1,276,094 | $2.42 | $2.43 | $2.32 |
| 25 Aug 2026 | $2.40 | $0.12 | 5.26% | 2,484,873 | $2.30 | $2.46 | $2.19 |
| 24 Aug 2026 | $2.28 | $0.03 | 1.33% | 751,305 | $2.27 | $2.30 | $2.25 |
| 21 Aug 2026 | $2.25 | $-0.03 | -1.32% | 862,260 | $2.28 | $2.28 | $2.21 |
| 20 Aug 2026 | $2.28 | $0.04 | 1.79% | 1,163,405 | $2.25 | $2.28 | $2.20 |
| 19 Aug 2026 | $2.24 | $-0.02 | -0.88% | 1,153,356 | $2.26 | $2.28 | $2.23 |
| 18 Aug 2026 | $2.26 | $0.03 | 1.35% | 1,160,964 | $2.28 | $2.28 | $2.22 |
| 17 Aug 2026 | $2.23 | $-0.01 | -0.45% | 573,250 | $2.26 | $2.26 | $2.22 |
| 14 Aug 2026 | $2.24 | $0.01 | 0.45% | 994,361 | $2.25 | $2.26 | $2.21 |
| 13 Aug 2026 | $2.23 | $0.01 | 0.45% | 1,631,548 | $2.25 | $2.27 | $2.22 |
| 12 Aug 2026 | $2.22 | $0.00 | 0.00% | 1,938,700 | $2.15 | $2.24 | $2.15 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 28 Aug 2026 | Jason Martinez | Buy | 30,000 | $71,700 |
On-market trade.
|
| 28 Aug 2026 | Ingrid Player | Buy | 10,000 | $23,800 |
On-market trade.
|
| 01 Jul 2026 | Ian Kadish | Exercise | 37,678 | $75,732 |
Conversion of securities. 740,241 rights
|
| 01 Jul 2026 | Ian Kadish | Buy | 37,678 | $75,732 |
Conversion of securities.
|
| 24 Jun 2026 | James Hall | Transfer | 225,271 | $444,910 |
Off-market transfer. Assuming off market transfer
|
| 24 Jun 2026 | James Hall | Transfer | 225,271 | $444,910 |
Off-market transfer. Assuming off market transfer
|
| 24 Jun 2026 | James Hall | Buy | 51,300 | $100,701 |
On-market trade.
|
| 11 Jun 2026 | James Hall | Buy | 12,000 | $24,468 |
On-market trade.
|
| 02 Apr 2026 | James Hall | Issued | 2,779 | $6,615 |
Dividend Reinvestment Plan (DRP).
|
| 09 Mar 2026 | James Hall | Buy | 10,000 | $22,500 |
On-market trade.
|
| 06 Mar 2026 | Laura McBain | Buy | 8,474 | $19,913 |
On-market trade.
|
| 27 Feb 2026 | Ingrid Player | Buy | 25,000 | $60,402 |
On-market trade.
|
| 27 Feb 2026 | Kevin (Kai-Chung) Shaw | Buy | 28,000 | $68,040 |
On-market trade.
|
| 31 Dec 2025 | James Hall | Buy | 6,200 | $15,066 |
On-market trade.
|
| 22 Dec 2025 | Ian Kadish | Exercise | 34,233 | $82,843 |
Conversion of securities. 7,77,919 rights
|
| 22 Dec 2025 | Ian Kadish | Buy | 34,233 | $82,843 |
Conversion of securities.
|
| 16 Dec 2025 | Ian Kadish | Issued | 235,596 | $584,278 |
Issue of securities. 812,132 Rights
|
| 03 Oct 2025 | James Hall | Issued | 2,652 | $7,666 |
Dividend Reinvestment Plan (DRP).
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Andrew James Fay | Non-Executive Director | Jul 2022 |
Mr Fay brings to the Board over 35 years of experience in funds and investment management, including Chief Executive Officer and Chief Investment Officer roles at Deutsche Asset Management (Australia) Limited. He also held a few other senior investment roles at Deutsche Asset Management and previously at AMP Capital. From 1998 to 2006, he was a member of the Investment Board Committee of the Financial Services Council. Andrew is an experienced company director across ASX-listed, private and regulated entities and brings to the Board skills in finance and risk management, capital markets, executive remuneration frameworks, strategy, investment and corporate governance. Specifically, he has sector experience and expertise in financial services, including investment, funds, property and infrastructure management. External Roles: Chair of Growthpoint Properties Australia Chair of Utilities of Australia Pty Ltd Non-Executive Director of National Cardiac Pty Ltd.
|
| Ms Ingrid Anne Player | Non-Executive Director | Aug 2023 |
Ms Player is an experienced former Executive and Non-Executive Director with international commercial and regulatory experience in mergers and acquisitions, corporate governance, capital developments, risk and sustainability that spans different markets and industries in Australia and Europe. Her experience includes her senior executive roles with leading healthcare providers, where she worked closely with the Board to deliver various capital raisings, retail listed notes, and debt finance deals. She was also instrumental in leading the integration of more than 50 businesses into the Group, implementing the first Reconciliation Action Plan and establishing diversity targets throughout the organization. Her roles included Group Executive for Legal, Governance and Sustainability as well as General Counsel and Company Secretary. She is the Chair of the Risk, Compliance and Sustainability Committee. External roles: Non-Executive Director of Cleanaway Waste Management Limited Non-Executive Director of Cogstate Limited Non-Executive Director of the Epworth Foundation.
|
| Mr James Tobias Hall | Non-Executive DirectorNon-Executive Chairman | Sep 2023 |
Mr Hall has healthcare executive leadership experience in Australia and New Zealand and is an experienced Board and Committee Chair. From 2014 to 2022, Toby was the Group CEO of St Vincent Health Australia, the non-government provider of hospital and care services in the country. He has also overseen multi-site, for-profit-generating businesses at both board and executive levels in employment services, early learning services and aged care. Toby also has extensive involvement in policy development at a federal level in Australia, having served on committees established by Prime Ministers, Deputy Prime Ministers, Health Ministers, Employment and Social Services Ministers. External Roles: Serves as Non-Executive Director of Ingenia Communities Group and Director of Papua New Guinea Sustainable Development Fund and PT Siloam International Hospitals Tbk.
|
| Ms Laura Nicole McBain | Non-Executive Director | Dec 2024 |
Ms McBain is an experienced Executive and Non-Executive Director with a background in the food, beverage, and consumer industries, specialising in brand development, fast growth, corporate governance, financial oversight, and business development. Her experience includes senior leadership roles as Managing Director at Bellamy's Australia Limited and Maggie Beer Holdings Limited, where she drove strategic growth, operational excellence, and stakeholder engagement. In recognition of her leadership and contributions, Laura was named the 2013 Telstra Tasmanian Businesswoman of the Year and the Telstra Australian Businesswoman of the Year (Private and Corporate). Previously, she was a Non-Executive Director of Lark Distilling Ltd and Export Finance Australia. She is the Member of the Risk, Compliance and Sustainability Committee.
|
| Dr Kevin (Kai-Chung) Shaw | Non-Executive Director | Dec 2024 |
Mr Shaw is a qualified radiologist with sub-specialty training in neuroradiology and musculoskeletal imaging. He is the current Director of Medical Imaging at Barwon Health. He obtained his medical degree from Monash University in 2006 and completed his radiology training at Royal Melbourne Hospital. Kevin is also a Clinical Professor at Deakin Medical School. He is a past examiner for the Royal Australian and New Zealand College of Radiologists (RANZCR) and previously sat on the College Anatomy Exam Review Panel. He has been an MRI Clinical Reviewer for RANZCR since 2014. He is the Member of the Risk, Compliance and Sustainability Committee.
|
| Mr Manish Mittal | Non-Executive Director | Feb 2025 |
Mr Mittal is professionally focused on MRI, including musculoskeletal, prostate and cardiac imaging in addition to extensive experience in neuroradiology and abdominal radiology. He also has experience in hospital settings including emergencies and trauma. Manish has worked within IDX and its precursor businesses for over 18 years and held senior clinical governance and leadership roles across a few IDX business units enabling the development of his deep understanding of the IDX operating businesses. He is the Member of the Risk, Compliance and Sustainability Committee.
|
| Mr Jason Martinez | Chief Executive OfficerExecutive DirectorManaging Director | Aug 2026 |
Mr Martinez has 20 years' experience in the diagnostic imaging, health and medical sectors. Mr Martinez served as Executive General Manager for NSW, ACT and WA at I-MED Radiology.
|
| Mr John J Merity | Company Secretary | Jun 2024 |
-
|
| Craig White | CFO |
-
|
|
| John J Merity | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 85,886,682 | 23.02% |
| J P Morgan Nominees Australia Pty Limited | 68,044,538 | 18.24% |
| Citicorp Nominees Pty Limited | 64,008,263 | 17.16% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 10,502,876 | 2.82% |
| BNP Paribas Noms Pty Ltd <Global Markets> | 10,379,181 | 2.78% |
| BNP Paribas Noms (Nz) Ltd | 7,826,172 | 2.10% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 6,224,275 | 1.67% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 5,874,991 | 1.57% |
| HSBC Custody Nominees (Australia) Limited <NT Commwlth Super Corp A/c> | 4,379,374 | 1.17% |
| BNP Paribas Noms Pty Ltd | 4,257,543 | 1.14% |
| Kim New Holdings Pty Ltd | 3,389,045 | 0.91% |
| Lethean Holdings Pty Ltd <The Howitt No 8 A/c> | 2,944,760 | 0.79% |
| Idinoc Pty Ltd <J & R Conidi Family A/c> | 2,502,713 | 0.67% |
| Firbar Pty Ltd <The Howitt No 4 A/c> | 2,357,230 | 0.63% |
| First Samuel Ltd ACN 086243567 <ANF ITS MDA Clients A/c> | 2,340,923 | 0.63% |
| Masfen Securities Limited | 2,250,000 | 0.60% |
| Mittal Holdings Pty Ltd <Howitt No 12 A/c> | 2,085,907 | 0.56% |
| Citicorp Nominees Pty Limited <143212 NMMT Ltd A/C> | 1,937,341 | 0.52% |
| Wyndham Salter Pty Ltd <The Howitt No 10 A/c> | 1,692,947 | 0.45% |
| Warbont Nominees Pty Ltd <Settlement Entrepot A/c> | 1,677,944 | 0.45% |